Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Nurix Therapeutics (NRIX – Research Report), Nektar Therapeutics (NKTR – Research Report) and Alnylam Pharma (ALNY – Research Report).
Nurix Therapeutics (NRIX)
Needham analyst Gil Blum maintained a Buy rating on Nurix Therapeutics on October 7 and set a price target of $32.00. The company’s shares closed last Monday at $10.99, close to its 52-week low of $7.52.
According to TipRanks.com, Blum is ranked 0 out of 5 stars with an average return of
Nurix Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $42.50, which is a 286.4% upside from current levels. In a report issued on October 7, H.C. Wainwright also maintained a Buy rating on the stock with a $53.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Nektar Therapeutics (NKTR)
In a report issued on October 6, Mara Goldstein from Mizuho Securities maintained a Hold rating on Nektar Therapeutics, with a price target of $6.00. The company’s shares closed last Monday at $3.55, close to its 52-week low of $2.96.
According to TipRanks.com, Goldstein is a 2-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Nektar Therapeutics with a $5.23 average price target.
Alnylam Pharma (ALNY)
In a report issued on October 7, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Alnylam Pharma, with a price target of $430.00. The company’s shares closed last Monday at $186.82.
According to TipRanks.com, Trucchio has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Alnylam Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $236.68, which is a 21.7% upside from current levels. In a report issued on October 3, Citigroup also maintained a Buy rating on the stock with a $280.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on NRIX:
- Analysts Offer Insights on Technology Companies: Advanced Micro Devices (AMD), Semtech (SMTC) and VIZIO Holding (VZIO)
- Plus500’s Q3 Update Disappoints
- H.C. Wainwright Reaffirms Their Buy Rating on Aldeyra Therapeutics (ALDX)
- H.C. Wainwright Sticks to Its Buy Rating for Y-Mabs Therapeutics (YMAB)
- Sensei Biotherapeutics (SNSE) Receives a Hold from Berenberg Bank
